STCube, Inc.
KKRX:0520207,060.00
KRW
+60.00
(+0.86%)
ISIN
KR7052020005
Return %
Stock
S&P 500
1Y
-10.63
14.39
3Y
-19.59
81.42
5Y
6.67
68.62
Capital Structure
KRW
•
in mil. unless spec.Working Capital
KRW
•
in mil. unless spec.Growth Rates
KRW
•
in mil. unless spec.Quarterly Revenue
KRW
•
in mil. unless spec.Quarterly Earnings Per Share
KRW
•
in mil. unless spec.Quarterly Dividends Per Share
KRW
•
in mil. unless spec.Company Description
- CEO
- Hyun-Jin Chung
- Full Time Employees
- 16
- Sector
- Distribution services
- Industry
- Electronics distributors
- Address
- 2201, Trade Center Trade Tower, 511 Yeongdong-daero Seoul SL South Korea 6164
- IPO Date
- Jul 5, 2001
- Website
- stcube.com
- Similar Companies
- Business
- STCube, Inc. (052020.KQ) is a biopharmaceutical company that develops innovative immunotherapies targeting novel immune checkpoints for cancer treatment. The company offers a pipeline of anti-cancer drugs, including Nelmastobart (hSTC810 or STT-003), a first-in-class anti-BTN1A1 monoclonal antibody in Phase 1b/2 trials for solid tumors such as small cell lung cancer, colorectal cancer, lung cancer, head and neck cancer, breast cancer, prostate cancer, and pancreatic cancer; anti-PD-L1 and anti-PD-1 antibodies in preclinical stages; STT-005, STT-012, and STT-013 antibodies for various solid tumors; and STT-011, a small molecule inhibitor for pancreatic cancer. It provides proprietary platform technologies comprising the In vivo RNAi ICP target discovery platform for immune checkpoint protein identification; glycosylation-specific antibody development platform for masking glycosylation sites on target proteins; and ICP functional assay platform for in vivo and in vitro analytical methods. STCube operates primarily in the immuno-oncology segment, focusing on patients with relapsed or refractory solid tumors resistant to PD-1/PD-L1 therapies, with BTN1A1 expression mutually exclusive to PD-L1 in cancers like colon, lung, and breast. The company maintains research and development facilities in South Korea and a U.S. subsidiary, STCube Pharmaceuticals, in Gaithersburg, Maryland, near the NIH and FDA. Founded in 1989 and headquartered at 2201, Trade Center Trade Tower, 511 Yeongdong-daero, Gangnam-gu, Seoul, South Korea, STCube was formerly known as Schem Co., Ltd. until its name change in April 2008. In recent developments, STCube successfully completed the first-in-human Phase 1 clinical trial of Nelmastobart in 47 patients with advanced solid tumors in 2024, confirming its safety profile with mostly mild adverse events, no dose-limiting toxicities, and promising efficacy data including disease control, presented at the SITC annual meeting. Phase 1b combination trials of Nelmastobart with capecitabine in metastatic colorectal cancer and with paclitaxel in extensive-stage small cell lung cancer are ongoing, alongside plans for Phase 2 trials combining it with docetaxel in BTN1A1-positive non-small cell lung cancer. The company has secured collaborations with leading institutions, including MD Anderson Cancer Center, and initiated investigator-sponsored trials to advance biomarker-driven precision therapies.